P520 Thromboembolic and major adverse cardiovascular events among patients in the filgotinib clinical trial programme

Autor: J van der Woude, S Schreiber, L Peyrin-Biroulet, Z Szekanecz, E H Choy, P J Stiers, P Van Hoek, K Van Beneden, A de Haas, C Rudolph, H ten Cate

Publikováno v: Journal of Crohn's and Colitis. 17:i646-i649

Background The once-daily, oral, Janus kinase 1 preferential inhibitor filgotinib (FIL) is approved for the treatment of moderately to severely active rheumatoid arthritis (RA) and ulcerative colitis (UC) in the UK, the EU and Japan.1 To further unde

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::912daa445de5ea4934b459b16d506285
https://doi.org/10.1093/ecco-jcc/jjac190.0650

Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+:The pragmatic, multicenter, placebo-controlled GLORIA trial

Autor: L Hartman, M El Alili, M Cutolo, D Opris, JAP Da Silva, Z Szekanecz, F Buttgereit, P Masaryk, R Bos, MR Kok, S Paolino, VMH Coupé, WF Lems, M Boers

Publikováno v: GLORIA consortium 2022, ' Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+ : The pragmatic, multicenter, placebo-controlled GLORIA trial ', Seminars in Arthritis and Rheumatism, vol. 57, 152109 . https://doi.org/10.1016/j.semarthrit.2022.152109
Seminars in Arthritis and Rheumatism, 57:152109. W.B. Saunders Ltd

© 2022Background: The GLORIA placebo-controlled trial found a favorable balance of benefit and harm for two years of prednisolone (5 mg/day) as add-on treatment for rheumatoid arthritis (RA) patients aged 65+. This study evaluated the cost-effective

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3086d7a9723b67930b5c7b45e596eabd
https://research.vumc.nl/en/publications/cebe6386-07bb-4da6-b62a-c3c5673a2f6e

Impact du risque cardiovasculaire initial sur l’incidence des événements cardiovasculaires indésirables majeurs dans le programme de développement clinique du tofacitinib dans la polyarthrite rhumatoïde

Autor: M. Dougados, C. Charles-Schoeman, Z. Szekanecz, J.T. Giles, S.R. Ytterberg, D.L. Bhatt, G.G. Koch, I. Vranic, J. Wu, C. Wang, K. Kwok, S. Menon, C.A. Connell, A. Yndestad, J.L. Rivas, M.H. Buch

Publikováno v: Revue du Rhumatisme. 89:A68-A69

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6f674fe3f816921dc7142641de860b86
https://doi.org/10.1016/j.rhum.2022.10.093

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

POS0520 ASSOCIATION BETWEEN BASELINE STATIN TREATMENT AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF ORAL SURVEILLANCE

Autor: J. T. Giles, C. Charles-Schoeman, M. H. Buch, M. Dougados, Z. Szekanecz, S. R. Ytterberg, G. G. Koch, J. Wu, C. Wang, K. Kwok, S. Menon, Y. Chen, T. Y. Cesur, J. L. Rivas, A. Yndestad, A. Diehl, D. L. Bhatt

Publikováno v: Annals of the Rheumatic Diseases. 81:518-519

BackgroundORAL Surveillance (NCT02092467) was a post-authorisation safety study of tofacitinib vs tumour necrosis factor inhibitors (TNFi) in patients (pts) with rheumatoid arthritis (RA) aged ≥50 years (yrs) with ≥1 additional cardiovascular (CV

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::aafbe0539a4cd46c0cc90fa4602d10f4
https://doi.org/10.1136/annrheumdis-2022-eular.1255